A Race Against Time: The CureDuchenne Clinic’s Remarkable Efforts Bring Life-Changing Gene Therapy to Young Boy on the Brink of Ineligibility.
FibroGen announced topline data from their Phase 3 trials of their novel antifibrotic agent, pamrevulmab, a connective tissue growth factor antibody for the treatment for ambulatory individuals with Duchenne. While pamrevlumab was generally safe and well tolerated, the study unfortunately did not meet the primary endpoint. Pamrevlumab also failed to meet its primary endpoint in non-ambulatory individuals earlier this year.
Annual Event Features Dinner, Drinks, Raffles, Fall Fashion Show Preview and More to Raise Funds to Help Find a Cure for Duchenne Muscular Dystrophy AUSTIN, Texas (August 15, 2023) – CureDuchenne, […]
Event Has Raised More Than $5.3 Million to Find a Cure for Duchenne Muscular Dystrophy NEWPORT BEACH, Calif., (August 14, 2023) – CureDuchenne, a leading global nonprofit focused on finding […]
The two-lane highway stretches to an infinite distance. It’s just you, the droning road noise and the horizon. It’s a time to think and ask yourself questions you never had […]
Raising Awareness and Funding Duchenne Research: Christian Hogan and his 22-year-old son Micah, who has Duchenne, envisioned this event after attending a reggae show in Long Beach several years ago.
NEWPORT BEACH, Calif., (July 31, 2023) — The second annual Cali-RAD Fest (Reggae Against Duchenne) will return to The Beach House in Mission Beach on September 2, 2023, to benefit […]
– First participant is expected to be dosed in September 2023 with data anticipated in the second half of 2024 – – Cash runway extended through the end of 2025 […]
The positive results from the 12-month ARCH study support the hypothesis that a reduction in contraction-induced muscle damage in muscular dystrophies, associated with EDG-5506 administration, has the potential to preserve and improve muscle function while preventing disease progression in dystrophinopathies. Observations from ARCH identified key factors, including the optimal dosing strategy of EDG-5506, for the design of a potentially registrational trial. A pivotal cohort, GRAND CANYON, has been added to the CANYON study and is anticipated to begin enrollment in the third quarter of 2023.
